# US 11,304,973 B2 · Botulinum toxin and colloidal silver particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,304,973 B2
- Document ID: US11304973B2
- Status: Granted
- Kind: B2
- Application number: 15/415,808
- Filed: 2017-01-25
- Published: 2017-07-13
- Granted: 2022-04-19
- Earliest claimed: 2014-09-02
- Assignees: American Silver, LLC; Dr. Andrew Willoughby Inc.
- Applicants: Keith William Moeller; Andrew J. M. Willoughby
- Inventors: Keith William Moeller; Andrew J. M. Willoughby
- Web page: https://patentgrep.com/patent/US11304973B2

## CPC

- A61K 33/38: Silver; Compounds thereof
- A61K 8/042: {Gels}
- A61K 8/044: {Suspensions}
- A61K 8/19: containing inorganic ingredients
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 8/66: Enzymes
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 47/02: Inorganic compounds
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 19/08: Anti-ageing preparations
- A61K 2800/41: Particular ingredients further characterized by their size
- A61K 2800/413: Nanosized, i.e. having sizes below 100 nm
- A61K 2800/882: Mixing prior to application
- A61K 2800/91: Injection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Botulinum toxin is combined with colloidal silver particles to provide improved compositions for use in medical and cosmetic treatments.

## Claims

### Claim 1

A method of treating wrinkles, comprising
administering a composition by injection to a subject in need thereof, the composition comprising botulinum toxin (BTX), colloidal silver particles, and at least one of water, saline and buffer, the composition comprising from 10±5 ppm to 30±5 ppm colloidal silver particles for every 100 units of BTX suspended in the water, and wherein the colloidal silver particles are in the form of a stable and colorless colloidal suspension of silver particles having an interior of metallic silver and an exterior surface of ionic silver oxide, wherein at least 75% of the silver particles have diameters between 0.005 micrometers and 0.015 micrometers, and
storing the composition for a period of from 2 weeks to 4 months after preparation of the composition, prior to the administering of the composition to the subject; and
wherein the administration is effective to treat static or functional wrinkles for a period of 7.5 months to 10 months.

### Claim 2

A method of treating wrinkles, comprising
administering a composition by injection to a subject in need thereof, the composition comprising botulinum toxin (BTX), colloidal silver particles, and water, the composition comprising an amount of from 10±5 ppm to 30±5 ppm colloidal silver particles for every 100 units of BTX suspended in the water where the amount is effective to treat static or functional wrinkles for a period of 7.5 months to 10 months, and wherein the colloidal silver particles are in the form of a stable and colorless colloidal suspension of silver particles having an interior of metallic silver and an exterior surface of ionic silver oxide, wherein at least 75% of the silver particles have diameters between 0.005 micrometers and 0.015 micrometers.

### Claim 3 (depends on 2)

The method of claim 2 wherein the composition comprises about 30 ppm colloidal silver.

### Claim 4 (depends on 2)

The method of claim 2 wherein the composition comprises 30 ppm colloidal silver.